Role of deregulated microRNAs in breast cancer progression using FFPE tissue

Liang Chen1, Youhuai Li, Yebo Fu

  • 1Division of Genomic Medicine, Department of Medicine, The George Washington University School of Medicine and Health Sciences, Washington, District of Colombia, United States of America.

Plos One
|February 2, 2013
PubMed

Insights

MicroRNA (miRNA) deregulation in breast cancer is an early event, occurring during the transition from normal tissue to atypical ductal hyperplasia. This study identified key miRNAs and demonstrated the feasibility of using archived tissues for biomarker discovery.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • MicroRNAs (miRNAs) are key regulators of gene expression involved in cancer development.
  • Breast intraductal epithelial proliferations are classified into normal, atypical ductal hyperplasia (ADH), ductal carcinoma in situ (DCIS), and invasive ductal carcinoma (IDC).

Purpose of the Study:

  • To identify deregulated miRNAs during ductal breast cancer progression.
  • To investigate miRNA expression profiles in Formalin-Fixed, Paraffin-Embedded (FFPE) tissues from breast cancer patients.

Main Methods:

  • Tissue microdissection of normal, ADH, DCIS, and IDC samples.
  • RNA isolation and miRNA expression profiling.
  • miRNA knockdown experiments in breast cancer cell lines.

Main Results:

  • miR-21, miR-200b/c, miR-141, and miR-183 were consistently up-regulated across ADH, DCIS, and IDC stages compared to normal.
  • miR-557 was uniquely down-regulated in DCIS.
  • Significant miRNA deregulation was observed during the normal to ADH transition, suggesting an early event in tumorigenesis.
  • miR-21 knockdown restored the expression of MSH2 and SMAD7 in breast cancer cells.

Conclusions:

  • miRNA expression profiling of FFPE tissues is feasible for miRNA biomarker discovery in breast cancer.
  • Deregulation of miRNA expression is an early event in breast cancer development.
  • Identified candidate miRNAs (e.g., miR-21, miR-200b/c) warrant further investigation as potential biomarkers for ductal breast cancer.

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...